Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million
(Thomson Reuters ONE) -
Novartis International AG /
Novartis announces divestiture of influenza vaccines business to CSL for USD 275
million
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* CSL to acquire Novartis influenza vaccines business, including development
pipeline, for USD 275 million
* Announcement follows a transaction announced on April 22, 2014 to divest the
non-influenza segments of Novartis Vaccines to GlaxoSmithKline
Basel, Switzerland, October 26, 2014 - Novartis today announced it has entered
into a definitive agreement to divest its influenza vaccines business to CSL
Limited (CSL) for an agreed price of USD 275 million. This transaction requires
regulatory approvals and is expected to close in the second half of 2015.
CSL has more than 40 years of experience in the influenza vaccines business and
operates in 27 countries with more than 13,000 employees worldwide. In addition
to vaccines, CSL has established businesses in plasma-driven therapies,
pharmaceuticals, antivenoms and immunohemotology. The Novartis influenza
vaccines unit will be combined with CSL's subsidiary, bioCSL.
"In CSL, we have found not only an owner for the influenza business that shares
our commitment to protecting public health, but also a strong growth platform
for the business and our associates," said Joseph Jimenez, CEO of Novartis.
The Novartis influenza vaccines business has a strong track record of delivering
almost 1 billion doses of seasonal and pandemic influenza vaccines globally over
the last 30 years. The company was the first and only manufacturer with the
flexibility of two production technologies - egg-based vaccines for seasonal,
pandemic and pre-pandemic, and cell-culture-based vaccines for antibiotic-free
production with the potential for rapid scale-up to protect against pandemic
threats. The business also benefits from access to a proprietary adjuvant
platform and leadership in pandemic preparedness.
Novartis remains fully committed to the influenza business during the transition
period to closing, including honoring agreements with customers, research and
development for influenza vaccines and product launches.
Related transactions and deal terms
Until the transaction with CSL is completed, Novartis will continue to operate
its influenza vaccines business and report its results under discontinuing
operations. The influenza vaccines business will be reported together with the
non-influenza business until such time as the non-influenza vaccines business is
divested to GlaxoSmithKline plc (GSK) as part of the previously announced
transaction.
As a result of today's announcement, IFRS requires a separate valuation of the
influenza vaccines assets. This immediately triggers the recognition of an
exceptional impairment charge of approximately USD 1.1 billion (pre-tax) as the
book value of the influenza vaccines assets are above the selling price. This
charge is a non-cash accounting impact and will be excluded from the Group's
core results. Upon closing the deal with GSK for the remaining non-influenza
vaccines business, Novartis expects to record a substantial one-time, non-cash
operating income gain, which would more than compensate for the impairment
charge associated with the influenza vaccines transaction.
On April 22, 2014, Novartis announced that it had reached a definitive agreement
with GSK to exchange certain assets, building global leadership in key segments
and focusing the Novartis portfolio. Under the agreement, which is
interconditional, Novartis would strengthen the company's innovative
pharmaceuticals business by acquiring GSK oncology products, and would divest
Novartis Vaccines (excluding influenza) to GSK. The two companies would also
create a joint venture, combining their consumer divisions to create a world-
leading consumer healthcare business. Separately, Novartis announced a
definitive agreement with Eli Lilly and Company (Lilly) to divest its Animal
Health Division, further focusing its portfolio on the leading businesses of
innovative pharmaceuticals, eye care and generics. These transactions are
subject to closing conditions. The Lilly transaction is expected to close in the
first quarter of 2015 and the GSK transaction is expected to close in the first
half of 2015.
As announced on April 22, 2014, Novartis also expects to record significant
additional one-time, non-cash operating income gains upon closing of the other
inter-conditional transactions with GSK and the separate transaction with Lilly.
These gains will also be excluded from the Group's core results.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "to acquire," "to divest," "expected," " will," "commitment,"
"potential," "committed," "growth platform," "to exchange," "inter-conditional,"
"would," "to create," "subject to," "expects," or similar terms, or by express
or implied discussions regarding the potential completion of the announced
transactions with CSL, GSK and Eli Lilly, or regarding potential future sales or
earnings of any of the businesses involved in the announced transactions, or of
the Novartis Group, and regarding any potential strategic benefits, synergies or
opportunities as a result of the announced transactions. You should not place
undue reliance on these statements. Such forward-looking statements are based on
the current beliefs and expectations of management regarding future events, and
are subject to significant known and unknown risks and uncertainties. Should one
or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those set
forth in the forward-looking statements. There can be no guarantee that the
proposed transactions will be completed in the expected form or within the
expected time frame or at all. Nor can there be any guarantee that Novartis will
be able to realize any of the potential strategic benefits, synergies or
opportunities as a result of the transactions. Neither can there be any
guarantee that Novartis or any of the businesses involved in the transactions
will achieve any particular future financial results in the future. In
particular, management's expectations could be affected by, among other things,
unexpected regulatory actions or delays or government regulation generally,
including an unexpected failure to obtain necessary government approvals for the
transactions, or unexpected delays in obtaining such approvals; the potential
that any other closing conditions for any of the transactions might not be met;
the potential that the strategic benefits, synergies or opportunities expected
from the transactions may not be realized or may take longer to realize than
expected; the uncertainties inherent in research and development, including
unexpected clinical trial results and additional analysis of existing clinical
data; the Company's ability to obtain or maintain proprietary intellectual
property protection; global trends toward health care cost containment,
including ongoing pricing pressures; general economic and industry conditions,
and other risks and factors referred to in Novartis AG's current Form 20-F on
file with the US Securities and Exchange Commission. Novartis is providing the
information in this press release as of this date and does not undertake any
obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-
counter and animal health products. Novartis is the only global company with
leading positions in these areas. In 2013, the Group achieved net sales of USD
57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9
billion (USD 9.6 billion excluding impairment and amortization charges).
Novartis Group companies employ approximately 135,000 full-time-equivalent
associates and sell products in more than 150 countries around the world. For
more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Liz Power
Novartis Global Media Relations Novartis Global Media Relations
+41 61 324 7999 (direct) +1 212 830 2466 (direct)
+41 79 593 4202 (mobile) +1 617 583 3015 (mobile)
eric.althoff(at)novartis.com elizabeth.power(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301
Thomas Hungerbuehler +41 61 324 8425 Susan Donofrio +1 862 778 9257
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1865897/655349.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
[HUG#1865897]
Unternehmensinformation / Kurzprofil:
Datum: 26.10.2014 - 22:00 Uhr
Sprache: Deutsch
News-ID 346956
Anzahl Zeichen: 11495
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 216 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
